Simparica Trio (40 - 60 kg)
ATC code
Species
Dogs.
Indications
For dogs with, or at risk from, mixed external and internal parasitic infestations. The veterinary medicinal product is exclusively indicated when use against ticks, fleas or mites and gastrointestinal nematodes is indicated at the same time. The veterinary medicinal product also provides concurrent efficacy for the prevention of heartworm disease, angiostrongylosis and thelaziosis.
Ectoparasites
- For the treatment of tick infestations. The veterinary medicinal product has immediate and persistent tick killing activity for 5 weeks against Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus and for 4 weeks against Dermacentor reticulatus;
- For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for 5 weeks;
- The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
- For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis). • For the treatment of demodicosis (caused by Demodex canis).
Gastrointestinal nematodes
For the treatment of gastrointestinal roundworm and hookworm infections:
- Toxocara canis immature adults (L5) and adults;
- Ancylostoma caninum L4 larvae, immature adults (L5) and adults; • Toxascaris leonina adults; • Uncinaria stenocephala adults.
Other nematodes
- For the prevention of heartworm disease (Dirofilaria immitis);
- For the prevention of angiostrongylosis by reducing the level of infection with immature adult (L5) stages of Angiostrongylus vasorum.
- For the prevention of establishment of thelaziosis (adult Thelazia callipaeda eyeworm infection).
Dose to be administered and administration route
Oral use.
Dose
The veterinary medicinal product should be administered at a dose of 1.2–2.4 mg/kg of sarolaner, 0.024–0.048 mg/kg of moxidectin and 5–10 mg/kg of pyrantel in accordance with the following table:
|
Bodyweight (kg) |
Tablet strength 72 mg/1.44 mg/300 mg |
|
>40–60 kg |
1 |
To ensure a correct dosage, bodyweight should be determined as accurately as possible.
Method of administration
Tablets can be administered with or without food.
Simparica Trio tablets are palatable and readily consumed by the majority of dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.
Treatment schedule:
The treatment schedule should be based on veterinary diagnosis, the local epidemiological situation and/or the epidemiological situation of other areas the dog has visited or is going to visit. If based on veterinarian opinion re-administration(s) of the product is required, any subsequent administration(s) must follow the minimum 1month interval schedule.
The product should only be used in dogs when treatment of ticks / fleas / mites and gastrointestinal nematodes is indicated at the same time. In the absence of the risk of mixed co-infestation, a narrower spectrum parasiticide should be used.
Treatment of flea and tick infestations and gastrointestinal nematodes:
The veterinary medicinal product can be used as part of the seasonal treatment of fleas and ticks (replacing treatment with a mono-active flea and tick product) in dogs with diagnosed concurrent gastrointestinal nematode infections. A single treatment is efficacious for the treatment of gastrointestinal nematodes. After treatment of the nematode infections, further flea and tick treatment should be continued with a monoactive product.
Prevention of heartworm disease and angiostrongylosis:
A single administration also prevents lungworm disease (by reducing the immature adults (L5) of A. vasorum) and heartworm disease (D. immitis) for one month. When the product replaces another lungworm or heartworm preventive product, the first dose of the product should be given within a month of the last dose of the former veterinary medicinal product. In endemic areas, dogs should receive lungworm and/or heartworm preventive treatments at monthly intervals. It is recommended that heartworm prevention treatment should be continued until at least 1 month after the last exposure to mosquitoes.
Prevention of establishment of thelaziosis (adult Thelazia callipaeda eyeworm infection):
Monthly administration of the product prevents establishment of infection with adult Thelazia callipaeda eyeworm.
Treatment of demodicosis (caused by Demodex canis):
Administration of a single dose once monthly for two consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart. As demodicosis is a multifactorial disease, it is advisable to also treat any contributing, underlying conditions appropriately.
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis):
Administration of a single dose at monthly intervals for two consecutive months. Further monthly administrations of the product may be required based on clinical assessment and skin scrapings.
Adverse reactions
Dogs:
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Gastrointestinal signs (such as vomiting, diarrhoea)1 Systemic disorders (such as lethargy, anorexia)1 Neurological signs (such as tremor, ataxia, convulsions)2 |
1 In most cases these signs are mild and transient.
2 In most cases these signs are transient.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also section “Contact details” of the package leaflet.
TRUSTED SOURCE
